Chromosome 22q11.2 deletion syndrome (22q11.2DS), the most common cause of DiGeorge syndrome, is quite variable. Neonatal diagnosis traditionally relies on recognition of classic features and cytogenetic testing, but many patients come to attention only following identification of later onset conditions, such as hypernasal speech due to palatal insufficiency and developmental and behavioral differences including speech delay, autism, and learning disabilities that would benefit from early interventions. Newborn screening (NBS) for severe combined immunodeficiency (SCID) is now identifying infants with 22q11.2DS due to T cell lymphopenia. Here, we report findings in such neonates, underscoring the efficacy of early diagnosis.
A retrospective chart review of 1350 patients with 22q11.2DS evaluated at the Children’s Hospital of Philadelphia identified 11 newborns with a positive NBS for SCID.
Five out of 11 would have been diagnosed with 22q11.2DS without NBS, whereas early identification of 22q11.2DS in 6/11 led to the diagnosis of significant associated features including hypocalcemia, congenital heart disease (CHD), and gastroesophageal reflux disease that may have gone unrecognized and therefore untreated.
Our findings support rapidly screening infants with a positive NBS for SCID, but without SCID, for 22q11.2DS even when typically associated features such as CHD are absent, particularly when B cells and NK cells are normal. Moreover, direct NBS for 22q11.2DS using multiplex qPCR would be equally, if not more, beneficial, as early identification of 22q11.2DS will obviate a protracted diagnostic odyssey while providing an opportunity for timely assessment and interventions as needed, even in the absence of T cell lymphopenia.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Rivers L, Gaspar HB. Severe combined immunodeficiency: recent developments and guidance on clinical management. Arch Dis Child. 2015;100:667–72.
Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015;39:194–205.
Chinn IK, Shearer WT. Severe combined immunodeficiency disorders. Immunol Allergy Clin N Am. 2015;35(4):671–94.
Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC. Retrospective study of 240 patients with severe combined immunodeficiency transplanted from 2000-2009: a report from the primary immune deficiency treatment consortium of North America. Biol Blood Marrow Transplant. 2014;20(2S):S24–5.
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for SCID in 11 screening programs in the US. JAMA. 2014;312(7):729–38.
Cirillo E, Giardino G, Gallo V, D’Assante R, Grasso G, Romano R, et al. Severe combined immunodeficiency – an update. Ann N Y Acad Sci. 2015;1356:90–106.
Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children Report. Newborn Screening for Severe Combined Immunodeficiency Disorder. Health Resources & Services Administration; 2011. 1–21.
Newborn Screening for Severe Combined Immunodeficiency (SCID) in the United States. Jeffrey Modell Foundation. http://www.info4pi.org/town-hall/newborn-screening. Updated May 8, 2017.
Gaspar HB, Hammarstrom K, Mahlaoui N, Borte M, Borte S. The case for mandatory newborn screening for severe combined immunodeficiency (SCID). J Clin Immunol. 2014;34(4):393–297.
PerkinElmer offers first commercially available newborn screen for severe combined immunodeficiency (SCID) in Europe & the Middle East [news release].Waltham, MA: PerkinElmer, Inc.; August 29, 2013. http://ir.perkinelmer.com/releasedetail.cfm?releaseid=787808. Accessed 11 Nov 2016.
Norway approves pilot project for SCID newborn screening [news release]. International Patient Organisation for Primary Immunodeficiencies; March 18, 2015. http://www.ipopi.org/index.php?mact=News,cntnt01,detail,0&cntnt01articleid=563&cntnt01origid=173&cntnt01detailtemplate=detalj&cntnt01returnid=63. Accessed 11 Nov 2016.
Madkaikar M, Aluri J, Gupta S. Guidelines for screening, early diagnosis and management of severe combined immunodeficiency (SCID) in India. Indian J Pediatr. 2016;83(5):455–62.
Baker MW, Grossman WJ, Laessig TH, Hoffman GL, Brokopp CD, Kurtycz DF, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124(3):522–7.
Kwan A, Church JA, Cowan MK, Agarwal R, Kapoor N, Kohn DB, et al. Newborn screening for SCID and T cell lymphopenia in California: results of the first two years. J Allergy Clin Immunol. 2013;132(1):140–50.
Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.
Comeau AM, Hale JE, Pai SY, Bonilla FA, Notarangelo LD, Pasternack MS, et al. Guidelines for implementation of population-based newborn screening for severe combined immunodecificeny. J Inherit Metab Dis. 2010;33(S2):S273–81.
Tomita-Mitchell A, Mahnke DK, Larson JM, Ghanta S, Feng Y, Simpson PM, et al. Multiplexed quantitative real-time PCR to detect 22q11.2 deletion in patients with congenital heart disease. Physiol Genomics. 2010;42A(1):52–60.
Barbaro M, Ohlsson A, Borte S, Jonsson S, Zetterström RH, King J, et al. Newborn screening for severe primary immunodeficiency diseases in Sweden – a 2-year pilot TREC and KREC screening study. J Clin Immunol. 2017;37(1):51–60.
Framme JL, Borte S, von Döbeln U, Hammarström L, Óskarsdóttir S. Restrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. J Clin Immunol. 2014;34(4):514–9.
McDonald-McGinn DM, Emanuel BS, Zackai EH. 22q11.2 deletion syndrome. In: R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.), GeneReviews, University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK1523 /, 1999 (accessed 12/12/2016).
Grati FR, Molina Gomes D, Ferreira JC, Dupont C, Alesi V, Gouas L, et al. Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn. 2015;35:801–9.
McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/Velocardiofacial syndrome). Medicine (Baltimore). 2011;90(1):1–18.
Maggadottir SM, Sullivan KE. The diverse clinical features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome). J Allergy Clin Immunol Pract. 2013;1(6):589–94.
McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JAS, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:1–19.
Sullivan KE. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/Velocardiofacial syndrome. Immunol Allergy Clin N Am. 2008;28:353–66.
Jawad AF, McDonald-McGinn DM, Zackai EH, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. 2001;139(5):715–23.
Allenspach E, Rawlings DJ, Scharenberg AM. X-linked severe combined immunodeficiency. GeneReviews [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK1410/. Published August 26, 2003. Updated April 14, 2016. Accessed 11 Nov 2016.
Wilson JM, Jungner YG. Principles and practice of screening for disease. Public health papers 34. Geneva: World Health Organization; 1968.
Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Newborn screening panel and system. Am Coll Med Genet Newborn Screen Exp Group. 2006;8(5S):12S–53S.
Ross LF, Saal HM, David KL, Anderson RR. American Academy of Pediatrics, American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet Med. 2013;15(3):234–45.
Bales AM, Zaleski CA, McPherson EW. Patient and family experiences and opinions on adding 22q11 deletion syndrome to the newborn screen. J Genet Couns. 2010;19:526–34.
Bales AM, Zaleski CA, McPherson EW. Newborn screening programs: should 22q11 deletion syndrome be added? Genet Med. 2010;12:135–44.
Carmichael N, Tsipis J, Windmueller G, Mandel L, Estrella E. “is it going to hurt?”: the impact of the diagnostic odyssey on children and their families. J Genet Couns. 2014;34:325–35.
Vogel BH, Bonagura V, Weinberg GA, Ballow M, Isabelle J, DiAntonio L, et al. Newborn screening for SCID in New York state: experience from the first two years. J Clin Immunol. 2015;34(3):289–303.
Oskardóttir S, Persson C, Eriksson BO, Fasth A. Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr. 2005;164(3):146–53.
Sullivan KE, Burrows E, McDonald-McGinn DM. Healthcare utilization in chromosome 22q11.2 deletion patients with cardiac disease and low T cell counts. Am J Med Genet A. 2016;170(6):1630–4.
Kobrynski LJ, Yazdanpanah GK, Koontz D, Lee FK, Vogt RF. MALDI-TOF-MS assay to detect the hemizygous 22q11.2 deletion in DNA from dried blood spots. Clin Chem. 2016;62(1):287–92.
Pretto D, Maar D, Yrigollen CM, Regan J, Tassone F. Screening newborn blood spots for 22q11.2 deletion syndrome using multiplex droplet digital PCR. Clin Chem. 2015;61(1):182–90.
Sørensen KM, Agergaard P, Olsesn C, Andersen PS, Larsen LA, Østergaard JR, et al. Detecting 22q11.2 deletion by use of multiplex ligation-dependent probe amplification on DNA from neonatal dried blood spot samples. J Mol Diagn. 2010;12(2):147–51.
The authors would like to thank the patients with 22q11.2 deletion syndrome and their families for their generous contributions to this and related research studies. The authors also express gratitude to the students, research assistants, and staff affiliated with the 22q and You Center at the Children’s Hospital of Philadelphia. Special thanks to Madeline Baxter, Danielle DiCicco, Alex Melchiorre, Adam Silverman, Dr. Kathryn Kadash-Edmondon, and Dr. Marta Unolt. This work was supported by grants from the National Institute of Health (PO1-HD070454) and the National Institute of Mental Health (R01 MH087636-01A1 and 1U01MH101720-02).
This work was supported by grants from the National Institute of Health (PO1-HD070454) and the National Institute of Mental Health (R01 MH087636-01A1 and 1U01MH101720-02).
Conflict of Interest
Professor McDonald-McGinn has given lectures on 22q11.2DS for Natera. The remaining authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Barry, J.C., Crowley, T.B., Jyonouchi, S. et al. Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency. J Clin Immunol 37, 476–485 (2017). https://doi.org/10.1007/s10875-017-0403-9
- 22q11.2 deletion
- DiGeorge syndrome
- newborn screening